UNSPSC 51312311: Diphenhydramine methiodide

This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C18H24NO.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CTN47N39PR, chemically known as ammonium, (2-(diphenylmethoxy)ethyl)trimethyl-, iodide, but more generally known as diphenhydramine methiodide, which bears US NIH Compound Identifier 26535. European Medicines Agency schedules diphenhydramine methiodide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07211MIG.

Most nations, for tariff purposes, schedule diphenhydramine methiodide under HS 29221980. SMILES: C[N+](C)(C)CCOC(C1CCCCC1)C2CCCCC2.[I-].

UNSPSC 51312311 Diphenhydramine methiodide is a Commodity code that in recent state and local procurement activity covers the supply of pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter medicines to public health agencies, state human services commissions, and cooperative purchasing alliances. The solicitations under this code reflect demand for both emergency-response medications and routine pharmacy supplies distributed through authorized wholesalers to support state and local government operations, health departments, and employee health benefit programs. Issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing organizations serving multiple jurisdictions; Seminole County, Florida and the Minnesota Department of Administration's Office of State Procurement appear as recent active buyers.

Activity is concentrated in Florida and Minnesota, with broader multi-state reach through cooperative purchasing vehicles such as MMCAP. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) exploring direct-to-manufacturer prescription programs. Vendors responding to these opportunities must comply with cGMP and Drug Supply Chain Security Act requirements, maintain substantial insurance coverage, and in cooperative purchasing contexts provide detailed NDC codes, SKUs, and pricing flexibility across multiple formats.